China National Pharmaceutical Holdings Limited was established on January 28, 1999. Through its wholly-owned subsidiary Hainan Hesheng Medical Biotechnology Co., Ltd. and its subsidiaries in China, the company is engaged in the development, production and marketing of medicines for human use. Its product portfolio includes basic generic drugs, first generic drugs and modern traditional Chinese medicine. 

Bio-pharmaceutical stocks rose in premarket trading, with LTGO up 4.6%, BLSM gaining 3.8% and CPHI rising 1.6%.

China Pharma Holdings (CPHI) shares fell 13.04% in premarket trading after the completion of a $5 million registered direct offering priced at $2.00 per share. The significant discount to recent trading levels has triggered dilution concerns among investors.

China Pharma Holdings (CPHI) falls 13.04% premarket after $5M registered direct offering completion

China Pharma Holdings' 15-minute chart has triggered a KDJ Death Cross and a Bearish Marubozu at 08:00 on October 10, 2026. This indicates a shift in momentum towards a downward trend, with a potential decrease in stock price. Sellers currently dominate the market, and it is likely that the bearish momentum will continue.China Pharma Holdings, Inc. (CPHI) has recently experienced a significant shift in technical indicators, signaling a bearish trend. On October 10, 2026, at 08:00, the stock’s 15-minute chart triggered a KDJ Death Cross and a Bearish Marubozu pattern, suggesting a potential decline in price and a shift in momentum toward the downside. These signals indicate that sellers are currently in control, and <a href="https://stockinvest.us/stock/CPHI">bearish momentum is expected to persist</a>.Earlier in August 2026, CPHI was downgraded to a "Strong Sell Candidate" with a technical score of -5.49, reflecting a deteriorating technical outlook. The stock had already fallen by -6.61% in the previous trading session, closing at $1.13, and had experienced a <a href="https://stockinvest.us/stock/CPHI">-25.66% decline over two weeks</a>. Despite a short-term rising trend, the stock is now positioned near the lower boundary of that trend, raising concerns about a potential reversal.Technical indicators, including the Moving Averages and MACD, continue to issue sell signals, reinforcing the bearish outlook. The stock is considered "very high risk" due to <a href="https://stockinvest.us/stock/CPHI">volatility and occasional low liquidity</a>. Investors are advised to monitor key support levels and consider the broader technical context before making trading decisions.

惠普森医药

China Pharma Holdings: KDJ Death Cross, Bearish Marubozu Triggered on 15min Chart

China Pharma Holdings's 15-minute chart has recently exhibited a KDJ Death Cross and a Bearish Marubozu pattern on August 10th, 2026 at 11:30. This indicates a shift in the momentum of the stock price towards a downward trend, with a potential for further depreciation. The sellers appear to be in control of the market, and the bearish momentum is likely to persist.China Pharma Holdings Inc (CPHI) has recently shown bearish technical signals on its 15-minute chart, including a KDJ Death Cross and a <a href="https://www.cnn.com/markets/stocks/CPHI">Bearish Marubozu pattern observed</a> on August 10, 2026, at 11:30. These patterns suggest a shift in momentum toward a downward trend, with sellers currently dominating the market. The Bearish Marubozu, characterized by a long bearish candle with no upper shadow, indicates <a href="https://www.cnn.com/markets/stocks/CPHI">strong selling pressure</a> and a potential continuation of the downward movement.Recent price action shows that CPHI closed at $1.20 on the last trading day, reflecting a <a href="https://intellectia.ai/stock/CPHI/forecast">-4.76% decline</a>. The stock has experienced significant intraday volatility, with a <a href="https://intellectia.ai/stock/CPHI/forecast">23.68% fluctuation between</a> a low of $1.14 and a high of $1.41. Over the past 10 days, the stock has declined in four sessions, with a <a href="https://intellectia.ai/stock/CPHI/forecast">cumulative drop of -26.32%</a>. Additionally, the stock is currently below its 200-day simple moving average and <a href="https://www.cnn.com/markets/stocks/CPHI">Trading within the middle</a> of its 52-week range.Technical indicators show a mixed outlook, with <a href="https://intellectia.ai/stock/CPHI/forecast">four bullish and three bearish signals</a>. While some indicators, such as the Stochastic Oscillator and MACD, suggest potential for a rebound, others like the <a href="https://intellectia.ai/stock/CPHI/forecast">Awesome Oscillator and Momentum indicators</a> remain bearish. The moving average analysis also reveals a bearish bias in the short term, with the <a href="https://intellectia.ai/stock/CPHI/forecast">5-day SMA below the 250-day SMA</a>.Looking ahead, the stock is projected to trade between $1.58 and $2.31 in 2026, with <a href="https://intellectia.ai/stock/CPHI/forecast">potential for both gains and losses</a> depending on market conditions. Investors are advised to monitor <a href="https://intellectia.ai/stock/CPHI/forecast">key resistance and support levels</a> at $1.82, $2.09, $0.93, and $0.65.

Bio-pharmaceutical stocks fell in regular trading, with CPHI down 7.3%, RDGT falling 5.9% and COR sliding 0.6%.

CPHI News